Retention and expansion for startups under 20 people for healthcare and life sciences in North America

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install retention and expansion has to be shaped to that reality from day one.

The under-20-person version of retention and expansion is not a diluted enterprise playbook. It is keeping and growing the customers you already paid to acquire with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Retention and expansion is only useful here when it is pointed at both constraints at once.

Instrument gross and net revenue retention in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is treating CS as a support cost centre, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working retention and expansion function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing retention and expansion deliberately for this market rather than importing a playbook designed for somewhere else.